Pharmacokinetics, Safety, and Efficacy of Ixekizumab in Chinese Patients with Moderate-to-Severe Plaque Psoriasis: A Phase 1, Single- and Multiple-Dose Study

被引：0
|
作者：
Min Zheng
Xiang Chen
Feng Wang
Jisu Chen
Kimberley Jackson
Fan Yang
Christopher Payne
HongYing Li
YiHui Wang
ZiPei Xiao
Jie Zheng
机构：
[1] The Second Affiliated Hospital,Department of Dermatology
[2] Zhejiang University School of Medicine,Department of Dermatology
[3] Xiangya Hospital,Department of Dermatology, School of Medicine
[4] Central South University,undefined
[5] Lilly Suzhou Pharmaceutical Co. Ltd,undefined
[6] Eli Lilly and Company,undefined
[7] Eli Lilly and Company,undefined
[8] Rui Jin Hospital,undefined
[9] Shanghai Jiao Tong University,undefined
来源：
Advances in Therapy | 2023年 / 40卷
关键词：
Psoriasis; Interleukin-17A; Phase 1; Pharmacokinetics; Safety;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：3804 / 3816
页数：12
相关论文
共 50 条
  • [31] Safety and tolerability of ixekizumab: analysis of neutropenia in 7 clinical studies of moderate-to-severe plaque psoriasis
    Strober, B.
    Pangallo, B. A.
    Veenhuizen, M. F.
    Xu, W.
    Russell, J. M.
    Blauvelt, A.
    [J]. EXPERIMENTAL DERMATOLOGY, 2016, 25 (03) : E10 - E10
  • [32] Phase 3, open-label, randomized study of the pharmacokinetics, efficacy and safety of ixekizumab following subcutaneous administration using a prefilled syringe or an autoinjector in patients with moderate-to-severe plaque psoriasis (UNCOVER-A)
    Duffin, K. Callis
    Bagel, J.
    Bukhalo, M.
    Clement, I. J.
    Choi, S. L.
    Zhao, F.
    Gill, A.
    Pangallo, B.
    Shuler, C.
    Mallbris, L.
    Jackson, K.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 (01) : 107 - 113
  • [33] Efficacy and safety of ixekizumab (IXE) compared to ustekinumab (UST) in patients with moderate-to-severe plaque psoriasis: A randomised head-to-head trial
    Burkhardt, N.
    Reich, K.
    Lomaga, M.
    Henneges, C.
    Dossenbach, M.
    Wilhelm, S.
    Paul, C.
    [J]. AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2017, 58 : 43 - 43
  • [34] Pharmacokinetics, pharmacodynamics, and safety of single- and multiple-dose intravenous ceftobiprole in healthy Chinese participants
    Li, Wan-Zhen
    Wu, Hai-Lan
    Chen, Yuan-Cheng
    Guo, Bei-Ning
    Liu, Xiao-Fen
    Wang, Yu
    Wu, Ju-Fang
    Zhang, Jing
    [J]. ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (11)
  • [35] A single- and multiple-dose study to characterize the pharmacokinetics, safety, and tolerability of ceftolozane/tazobactam in healthy Chinese participants
    Liu, Na
    Wang, Xiaohong
    Zhu, Jixiang
    Basu, Sumit
    Wei, Yudong
    Yan, Bei
    Wang, Hui
    Colon-Gonzalez, Francheska
    Feng, Hwa-Ping
    Sun, Fang
    Li, Haiyan
    Zang, Yanqiao
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2023, 61 (03)
  • [36] Randomized, controlled study of bleselumab (ASKP1240) pharmacokinetics and safety in patients with moderate-to-severe plaque psoriasis
    Kumar, Mysore S. Anil
    Papp, Kim
    Tainaka, Ryo
    Valluri, Udaya
    Wang, Xuegong
    Zhu, Tong
    Schwabe, Christian
    [J]. BIOPHARMACEUTICS & DRUG DISPOSITION, 2018, 39 (05) : 245 - 255
  • [37] A Single- and Multiple-Dose Study To Characterize the Pharmacokinetics, Safety, and Tolerability of Imipenem and Relebactam in Healthy Chinese Participants
    Wang, Xiaohong
    Liu, Na
    Wei, Yudong
    Zhang, Shuang
    Li, Haiyan
    Yan, Bei
    Patel, Munjal
    Wang, Hui
    Boundy, Keith E.
    Colon-Gonzalez, Francheska
    Zang, Yanqiao
    Zhao, Xumin
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2021, 65 (03)
  • [38] The Safety of Ixekizumab in Chinese Adults with Moderate-to-Severe Plaque Psoriasis: Analyses from a Prospective, Single-Arm, Multicenter, 12-Week Observational Study
    Li, Ying
    Dang, Lin
    Lv, Chengzhi
    Lin, Bingjiang
    Tao, Juan
    Yu, Nan
    Deng, Ya
    Wang, Huiping
    Kang, Xiaojing
    Qin, Hui
    Chen, Rong
    Li, Jinnan
    Liang, Yunsheng
    Liang, Yanhua
    Shi, Yuling
    [J]. DRUG SAFETY, 2024, 47 (07) : 711 - 719
  • [39] Safety of tildrakizumab in a Phase 4 real-world study in patients with moderate-to-severe plaque psoriasis
    Vasquez, J. Gabriel
    Bhatia, Neal
    Schenkel, Brad
    Rozzo, Stephen J.
    Heim, Jayme
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB85 - AB85
  • [40] The effect of bodyweight on the efficacy and safety of ixekizumab: results from an integrated database of three randomised, controlled Phase 3 studies of patients with moderate-to-severe plaque psoriasis
    Reich, K.
    Puig, L.
    Mallbris, L.
    Zhang, L.
    Osuntokun, O.
    Leonardi, C.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 (07) : 1196 - 1207
12345